Objective To provide updated guidelines for pharmacologic management of juvenile
idiopathic arthritis (JIA), focusing on treatment of oligoarthritis, temporomandibular joint (TMJ) …

Objective To assess the benefit of the recombinant human interleukin‐1 receptor antagonist
anakinra in treating pediatric patients with secondary hemophagocytic lymphohistiocytosis ( …

Objective To provide recommendations for the management of juvenile idiopathic arthritis (JIA)
with a focus on nonpharmacologic therapies, medication monitoring, immunizations, and …

Importance Active pediatric COVID-19 pneumonia and MIS-C are two disease processes
requiring rapid diagnosis and different treatment protocols. Objective To distinguish active …

Objective To compare incidence rates of selected opportunistic infections among children
with and children without juvenile idiopathic arthritis (JIA). Methods Using US national …

Objective Systemic juvenile idiopathic arthritis–associated lung disease (SJIA‐LD) is a life‐threatening
disease complication. Key questions remain regarding clinical course and …

Background SARS-CoV-2 has been found to be exquisitely adept at triggering
autoimmunity and multiple new onset autoimmune diseases have been described as a post-infectious …

Background Henoch-Schonlein purpura (HSP) is a small vessel vasculitis that is characterized
by non-thrombocytopenic purpura, abdominal pain, arthritis, and glomerulonephritis. …

Importance Minimal data are available regarding the postdischarge treatment of multisystem
inflammatory syndrome in children (MIS-C). Objectives To evaluate clinical characteristics …

Recent development of new medications has changed the juvenile idiopathic arthritis (JIA)
treatment goal to inactive disease. With numerous options, how does a clinician choose …